DJIA 17,440.59 -127.94 -0.73%
NASDAQ 5,039.78 -48.85 -0.96%
S&P 500 2,067.64 -12.01 -0.58%
market minute promo

ONCONOVA THERAPEUTICS INC (NASDAQ: ONTX)

2.12 -0.17 (-7.42%)

Quote as of


company name or ticker

Recent Quotes

ONTX $2.12 -7.42%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.26
Previous Close $2.29
Daily Range $2.00 - $2.26
52-Week Range $2.00 - $5.78
Market Cap $46.0M
P/E Ratio -0.87
Dividend (Yield) $0.00 (0.0%)
Volume 45,480
Average Daily Volume 27,062
Current FY EPS -$2.07

Sector

Industry

ONCONOVA THERAPEUTICS INC (ONTX) Description

ONCONOVA THERAPEUTICS INC Website: http://www.onconova.com/

News & Commentary Rss Feed

This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!

A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.

Onconova Therapeutics (ONTX) Shows Strength: Stock Up 9.7% - Tale of the Tape

Piper Jaffray Upgrades Onconova Therapeutics To Overweight

Piper Jaffray Upgrades Onconova Therapeutics To Overweight

Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in H

Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at EHA Annual Meeting

Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at t

Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting

Onconova Therapeutics (ONTX) Looks Good: Stock Up 5.8% - Tale of the Tape

Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue? - Tale of the Tape

Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue? - Tale of the Tape

What's in Store for Autodesk (ADSK) in Q1 Earnings? - Analyst Blog

Why Onconova Therapeutics (ONTX) Might Surprise This Earnings Season - Tale of the Tape

Will Kite Pharma (KITE) Miss Earnings Estimates Yet Again? - Analyst Blog

Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog

See More ONTX News...